目的 探讨超声引导下经皮射频消融(RFA)治疗恶性肿瘤肝转移的应用价值.方法 回顾性分析2009年12月-2015年5月于我院接受超声引导下经皮RFA治疗的109例恶性肿瘤肝转移患者的临床及影像学资料.结果 109例肝转移癌患者中,单发31例(31/109,28.44％),多发78例(78/109,71.56％);肝转移病灶来源于结直肠、肺、乳腺、胃、胰腺、卵巢及前列腺的恶性肿瘤.共198个肝转移癌病灶中,直径＜3 cm者151个(151/198,76.26％),直径≥3 cm者47个(47/198,23.74％).治疗后1个月,187个(187/198,94.44％)病灶完全灭活,11个(11/198,5.56％)病灶存在残余活性.与治疗前比较,治疗后1个月患者肿瘤标志物指标明显改善(P均＜0.05).术中及术后并发症发生率6.42％ (7/109).结论 对于非手术适应证恶性肿瘤肝转移患者,超声引导下经皮RFA治疗相对安全、有效,短期内可局部控制肝内转移癌的活性.%Objective To investigate the application value of ultrasound-guided percutaneous radiofrequency ablation (RFA) in treatment of liver metastases of malignant tumor.Methods Clinical and imaging data of 109 patients with liver metastases of malignant tumor who underwent ultrasound-guided percutaneous RFA during December 2009 to May 2015 were retrospectively analyzed.Results There were 31 patients (31/109,28.44％) with single liver metastases and 78 patients (78/109,71.56％) with multiple lesions.The primary tumors included colorectal,lung,breast,gastric,pancreatic,ovarian and prostate carcinomas.Among all 198 liver metastases,there were 151 (151/198,76.26％) with diameter ＜ 3 cm and 47 (47/198,23.74％) with diameter ≥3 cm.One month after RFA,187 lesions (187/198,94.44％) were completely inactivated,while the other 11 lesions (11/198,5.56％) still had residual activity.One month later,the tumor markers improved obviously compared with those before treatment (all P＜0.05).The incidence of intraoperative and postoperative complications was 6.42％ (7/109).Conclusion Ultrasound-guided percutaneous RFA is a safe and effective treatment for patients with non-surgical indications of malignant liver metastases,which can partially control the survival activity of liver metastases.
展开▼
